PFIC caused by USP53 usually mild form of liver disease: Study
Progressive familial intrahepatic cholestasis (PFIC) caused by mutations in the USP53 gene results in a fairly mild form of the disease, with most of…
News
Sagimet planning Phase 3 trials of denifanstat in MASH, MASLD
Sagimet Biosciences is planning the launch of two Phase 3 clinical trials to test its oral therapy candidate denifanstat in people with fatty…
Software helps ID hard-to-interpret Alagille-causing gene mutations
Software tools may help predict whether certain hard-to-interpret mutations in the JAG1 gene affect splicing, a process that can direct how a protein is produced,…
Aligos planning for Phase 2 trial of treatment for hepatitis B
The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 1 drug-drug interaction study to evaluate the effects of certain drugs…
RTY-694 chosen as lead treatment candidate for liver disease PSC
Rectify Pharmaceuticals has selected the oral small molecule RTY-694 as its lead treatment candidate for primary sclerosing cholangitis (PSC) and plans are underway…
Early-onset pregnancy cholestasis increases risk of diabetes: Study
Women diagnosed with intrahepatic cholestasis of pregnancy (ICP) before 24 weeks of gestation, or about six months, are significantly more likely to develop gestational…
Study fully enrolled of Rezdiffra for well-compensated liver cirrhosis
A Phase 3 clinical trial testing Rezdiffra (resmetirom) in people with well-compensated cirrhosis, or irreversible liver scarring that still allows the liver to work, due…
Protein in blood may be liver scarring marker in biliary atresia
Higher levels of a protein called amyloid precursor protein (APP) in the blood may be a marker of fibrosis, or liver scarring, in biliary…
Zetomipzomib found safe in Phase 2a trial for autoimmune hepatitis
The safety monitoring committee of a Phase 2a clinical trial testing zetomipzomib in people with autoimmune hepatitis has found no major safety issues with…
Full approval on Ocaliva for primary biliary cholangitis delayed
The U.S. Food and Drug Administration (FDA) is still reviewing Intercept Pharmaceuticals’ application for full approval of Ocaliva (obeticholic acid) as a second-line…
